Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
Abstract Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-10-01
|
| Series: | Genome Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13073-017-0483-4 |
| _version_ | 1818409214802919424 |
|---|---|
| author | Hisham Abdelmotilib Andrew B. West |
| author_facet | Hisham Abdelmotilib Andrew B. West |
| author_sort | Hisham Abdelmotilib |
| collection | DOAJ |
| description | Abstract Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease. |
| first_indexed | 2024-12-14T09:56:04Z |
| format | Article |
| id | doaj.art-0c120c484f51411991b25077ea782442 |
| institution | Directory Open Access Journal |
| issn | 1756-994X |
| language | English |
| last_indexed | 2024-12-14T09:56:04Z |
| publishDate | 2017-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Genome Medicine |
| spelling | doaj.art-0c120c484f51411991b25077ea7824422022-12-21T23:07:22ZengBMCGenome Medicine1756-994X2017-10-01911310.1186/s13073-017-0483-4Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapyHisham Abdelmotilib0Andrew B. West1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at BirminghamCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at BirminghamAbstract Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.http://link.springer.com/article/10.1186/s13073-017-0483-4Epigenetic modificationHistone acetylationLewy body diseaseNeuroinflammationNeuroprotectionParkinson’s disease |
| spellingShingle | Hisham Abdelmotilib Andrew B. West Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy Genome Medicine Epigenetic modification Histone acetylation Lewy body disease Neuroinflammation Neuroprotection Parkinson’s disease |
| title | Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy |
| title_full | Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy |
| title_fullStr | Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy |
| title_full_unstemmed | Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy |
| title_short | Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy |
| title_sort | breathing new life into an old target pulmonary disease drugs for parkinson s disease therapy |
| topic | Epigenetic modification Histone acetylation Lewy body disease Neuroinflammation Neuroprotection Parkinson’s disease |
| url | http://link.springer.com/article/10.1186/s13073-017-0483-4 |
| work_keys_str_mv | AT hishamabdelmotilib breathingnewlifeintoanoldtargetpulmonarydiseasedrugsforparkinsonsdiseasetherapy AT andrewbwest breathingnewlifeintoanoldtargetpulmonarydiseasedrugsforparkinsonsdiseasetherapy |